JP2024525723A - インターロイキン－２３受容体の二環式ペプチド阻害剤 - Google Patents

インターロイキン－２３受容体の二環式ペプチド阻害剤 Download PDF

Info

Publication number
JP2024525723A
JP2024525723A JP2024501737A JP2024501737A JP2024525723A JP 2024525723 A JP2024525723 A JP 2024525723A JP 2024501737 A JP2024501737 A JP 2024501737A JP 2024501737 A JP2024501737 A JP 2024501737A JP 2024525723 A JP2024525723 A JP 2024525723A
Authority
JP
Japan
Prior art keywords
alkyl
phe
cyano
interleukin
bicyclic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525723A5 (https=
Inventor
サン，チェンザオ
ニーランカヴィル，サントーシュ
パッチ，レイモンド，ジェイ．
ソマニ，サンディープ
バロス，ステファニー，エー．
ジャン，ジン
ヘンドリック，チャールズ
ビアンキ，エリザベッタ
コスタンテ，ロベルト
インジェニート，ラファエル
ブランカ，ダニラ
バンダリ，アショク
フレデリック，ブライアン
チュン チャン，チャン
ジャン，ジエ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2024525723A publication Critical patent/JP2024525723A/ja
Publication of JP2024525723A5 publication Critical patent/JP2024525723A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
JP2024501737A 2021-07-14 2022-07-14 インターロイキン－２３受容体の二環式ペプチド阻害剤 Pending JP2024525723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221854P 2021-07-14 2021-07-14
US63/221,854 2021-07-14
PCT/US2022/037202 WO2023288017A2 (en) 2021-07-14 2022-07-14 Bicyclic peptide inhibitors of interleukin-23 receptor

Publications (2)

Publication Number Publication Date
JP2024525723A true JP2024525723A (ja) 2024-07-12
JP2024525723A5 JP2024525723A5 (https=) 2025-07-24

Family

ID=84920518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501737A Pending JP2024525723A (ja) 2021-07-14 2022-07-14 インターロイキン－２３受容体の二環式ペプチド阻害剤

Country Status (12)

Country Link
US (1) US20240352073A1 (https=)
EP (1) EP4370532A4 (https=)
JP (1) JP2024525723A (https=)
KR (1) KR20240034223A (https=)
CN (1) CN117980320A (https=)
AR (1) AR126457A1 (https=)
AU (1) AU2022310347A1 (https=)
CA (1) CA3226492A1 (https=)
MX (1) MX2024000761A (https=)
TW (1) TW202321275A (https=)
UY (1) UY39858A (https=)
WO (1) WO2023288017A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025076414A1 (en) * 2023-10-06 2025-04-10 The Children's Medical Center Corporation Compositions and methods for selecting a subject for inflammatory bowel disease treatment
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206254B (zh) * 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) * 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
JP7100034B2 (ja) * 2016-12-06 2022-07-12 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
WO2019034866A1 (en) * 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
CN111712509A (zh) * 2017-12-15 2020-09-25 詹森生物科技公司 作为sting激动剂的环状二核苷酸
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
UY39858A (es) 2023-02-28
KR20240034223A (ko) 2024-03-13
CA3226492A1 (en) 2023-01-19
EP4370532A2 (en) 2024-05-22
WO2023288017A3 (en) 2023-03-09
WO2023288017A2 (en) 2023-01-19
TW202321275A (zh) 2023-06-01
US20240352073A1 (en) 2024-10-24
MX2024000761A (es) 2024-04-18
CN117980320A (zh) 2024-05-03
AU2022310347A1 (en) 2024-02-29
EP4370532A4 (en) 2025-09-03
AR126457A1 (es) 2023-10-11

Similar Documents

Publication Publication Date Title
JP2024525723A (ja) インターロイキン－２３受容体の二環式ペプチド阻害剤
US12478617B2 (en) Lipidated peptide inhibitors of interleukin-23 receptor
EP4370531A2 (en) Peptide inhibitors of interleukin-23 receptor
JP7441955B2 (ja) インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP7670605B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
JP2025134806A (ja) インターロイキン２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
JP2023014346A (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP2022540154A (ja) インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
HK40111925A (zh) 白介素-23受体的脂化肽抑制剂
CN121335914A (zh) 白介素-23受体的肽抑制剂
HK40083331A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250714